Tag: Prescription Drugs
Real-World Study Shows Effectiveness of Ixekizumab for Psoriasis
Significant clinical improvements seen with and without induction therapy, with faster initial response with induction
Weight Loss After Antiobesity Medication Initiation Lowers Joint Revision Risk
Higher weight loss after initiating antiobesity meds linked to lower risk for revision of hip and knee replacement
Obinutuzumab Efficacious for Renal Response in Lupus Nephritis
More patients receiving obinutuzumab plus standard therapy versus standard therapy alone had a complete renal response at week 76
One in Six Patients in Phase 2 Cancer Trials Receive Drug When Eventually Approved
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit
Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia
Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab
Olpasiran Leads to Significant Reduction in Oxidized Phospholipids
Olpasiran leads to significant and sustained reduction in OxPL on apolipoprotein B
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
Lower risk for COPD exacerbations seen with SGLT-2 inhibitors and GLP-1 receptor agonists, but not with DPP-4 inhibitors
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
Lower likelihood seen for experiencing increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
Talazoparib + enzalutamide linked to improved survival for patients with mCRPC unselected for HRR gene alterations
De-Escalating DAPT to Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome
Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome
